Metraipolis › archive › dc_45dff8b37452

Fifteen-year real-world pharmacovigilance of multiple sclerosis disease-modifying therapies: adverse event profiles, drug-specific safety signals and clinical… — Europe PMC PMID:42947850

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42947850
DOI
10.3389/fneur.2026.1845881
License (as archived)
solo-consultazione
Archived
2026-11-01T04:02:48.721Z
SHA-256 of the archived text
205aaec530978446c255c125a38fb5dfff30d0ab83910f5c02aa6f777804efa5
Stable URL of this page
https://metraipolis.com/documento/dc_45dff8b37452

How to cite

Fifteen-year real-world pharmacovigilance of multiple sclerosis disease-modifying therapies: adverse event profiles, drug-specific safety signals and clinical… — Europe PMC PMID:42947850 — Europe PMC (en), https://europepmc.org/article/MED/42947850 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_45dff8b37452 (Metraipolis archive dc_45dff8b37452, sha256 205aaec530978446c255c125a38fb5dfff30d0ab83910f5c02aa6f777804efa5)
BibTeX
@misc{dc45dff8b37452,
  title = {Fifteen-year real-world pharmacovigilance of multiple sclerosis disease-modifying therapies: adverse event profiles, drug-specific safety signals and clinical… — Europe PMC PMID:42947850},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42947850},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_45dff8b37452; sha256 205aaec530978446c255c125a38fb5dfff30d0ab83910f5c02aa6f777804efa5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42947850. Agents can read the archived copy with the MCP tool read_document.